BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 25739827)

  • 1. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.
    Bachmann C; Brucker SY; Kraemer B; Rothmund R; Staebler A; Fend F; Wallwiener D; Grischke EM
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1475-80. PubMed ID: 25739827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Pelvic and Para-aortic Lymph Node Metastases in Optimally Cytoreduced Advanced Ovarian Cancer.
    Bachmann C; Bachmann R; Brucker SY; Staebler A; Fend F; Grischke EM; Wallwiener D
    Anticancer Res; 2015 Jun; 35(6):3479-84. PubMed ID: 26026113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
    Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment.
    Bachmann C; Bachmann R; Fend F; Wallwiener D
    J Cancer; 2016; 7(15):2241-2246. PubMed ID: 27994660
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.
    Powless CA; Aletti GD; Bakkum-Gamez JN; Cliby WA
    Gynecol Oncol; 2011 Sep; 122(3):536-40. PubMed ID: 21636114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery.
    Eoh KJ; Lee JY; Yoon JW; Nam EJ; Kim S; Kim SW; Kim YT
    Oncotarget; 2017 Jun; 8(23):37807-37816. PubMed ID: 27906676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses.
    Bogani G; Tagliabue E; Ditto A; Signorelli M; Martinelli F; Casarin J; Chiappa V; Dondi G; Leone Roberti Maggiore U; Scaffa C; Borghi C; Montanelli L; Lorusso D; Raspagliesi F
    Gynecol Oncol; 2017 Oct; 147(1):61-65. PubMed ID: 28779965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
    Cowan RA; Tseng J; Murthy V; Srivastava R; Long Roche KC; Zivanovic O; Gardner GJ; Chi DS; Park BJ; Sonoda Y
    Gynecol Oncol; 2017 Nov; 147(2):262-266. PubMed ID: 28888540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of pelvic and para-aortic node metastases in early-stage ovarian cancer.
    Bachmann C; Krämer B; Brucker SY; Stäbler A; Fend F; Wallwiener D; Grischke EM; Rothmund R
    Anticancer Res; 2014 Nov; 34(11):6735-8. PubMed ID: 25368283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of lymphadenectomy in node-positive epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Millan I; Iglesias E
    Int J Gynecol Cancer; 2012 Jul; 22(6):987-92. PubMed ID: 22706223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* Study.
    Saygili U; Guclu S; Uslu T; Erten O; Ture S; Demir N
    J Surg Oncol; 2002 Nov; 81(3):132-7. PubMed ID: 12407725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of lymphadenectomy in advanced ovarian cancer according to residual tumor status: A population-based study.
    Zhou J; Zhang WW; Zhang QH; He ZY; Sun JY; Chen QH; Wu SG
    Int J Surg; 2018 Apr; 52():11-15. PubMed ID: 29432972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
    Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
    Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer.
    Ataseven B; Grimm C; Harter P; Prader S; Traut A; Heitz F; du Bois A
    Gynecol Oncol; 2014 Dec; 135(3):435-40. PubMed ID: 25312398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?
    Cliby WA; Aletti GD; Wilson TO; Podratz KC
    Gynecol Oncol; 2006 Dec; 103(3):797-801. PubMed ID: 17052746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
    Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.